in vivo News and Research

RSS

Drug interactions in placenta may increase risk of birth defects or stunting fetal growth

To date, studies in pregnant women examining transport of drugs across the placenta are rare and inadequate, said Tomo Nabekura, PhD. Such knowledge could be vital to preserving fetal health. In a new laboratory study, Nabekura and colleagues have illuminated a piece of this puzzle, and the results hint that mothers taking new anti-hepatitis C and/or anti-HIV drugs along with anti-hypertensives or non-steroidal anti-inflammatories (NSAIDs) could be raising the risk of birth defects or stunting fetal growth, respectively.

15 Oct 2015

Sense oligonucleotide antidote reverses actions of antisense antithrombotic drug, prevents bleeding

Researchers from Isis Pharmaceuticals (Carlsbad, CA) and Prysis Biotechnologies (Pudong, Shanghai, China) have demonstrated proof-of-concept for using a sense oligonucleotide to undo the effects of an antisense drug, an antithrombotic agent in this novel study.

14 Oct 2015

VTT examines effectiveness of beauty patch using unique imaging technology

VTT Technical Research Centre of Finland has analysed the effectiveness of its beauty patch, using a technique for imaging live tissue to demonstrate the patch's beneficial effects on the skin. Preliminary results show that already after two weeks usage the patch together with cosmetic serum adds collagen, which helps skin tissue to stay supple.

14 Oct 2015

UW researchers use noninvasive light-based imaging technology to see inside the living brain

Researchers at the University of Washington have used a noninvasive light-based imaging technology to literally see inside the living brain, providing a new tool to study how diseases like dementia, Alzheimer's, and brain tumors change brain tissue over time.

13 Oct 2015

Glycan binding proteins modify parasite infection in cells of the heart muscle

Chagas disease is the main cause of infectious heart disease in Latin America. Researchers from the INGEBI and IBYME Institutes in Argentina explored the effect of glycan binding protein interactions between the human host and Typanosoma cruzi parasite. They found that a glycan binding protein expressed in humans modified the infection in cells of the heart muscle, showing the importance of galectins in the response to parasite infection.

12 Oct 2015

Artificial lung model could provide better understanding of health risks associated with airborne pollution

A life-sized artificial human lung created at the Technion-Israel Institute of Technology is the first diagnostic tool for understanding in real time how tiny particles move and behave in the deepest part of the human lungs (alveolar tissue).

9 Oct 2015

Michigan researchers use Raman spectroscopy to study various childhood diseases

Renishaw, a world leader in metrology and spectroscopy, reports on the use of its inVia confocal Raman microscope in the study of various diseases–with a major focus on childhood diseases–at the Children's Hospital of Michigan and Wayne State University.

6 Oct 2015

Novel prosthetic heart valve developed for treatment of mitral regurgitation

A team of researchers from the National University of Singapore (NUS) has developed a novel prosthetic heart valve, known as VeloX, which can be implanted through a small incision for the treatment of a serious heart valve disorder called mitral regurgitation. This is a condition in which the mitral valve on the left side of the heart does not close properly. The device is particularly beneficial to patients who are of high surgical risk or are unsuitable for existing clinical interventions.

6 Oct 2015

Leading cancer researchers address eight 'big questions'

Leading cancer researchers address eight of the "big questions" facing the field as part of the inaugural issue of Trends in Cancer, published by Cell Press.

30 Sep 2015

Glowing protein may replace fiber optic cable as light source in optogenetics research

Optogenetics has taken neuroscience by storm in recent years because the technique allows scientists to study the brain conveniently in animals, activating or inhibiting selected groups of neurons at the flip of a switch. Most often, scientists use a fiber optic cable to deliver light into the brain.

30 Sep 2015

MedUni Vienna researchers report new strategy for targeted treatment of ovarian cancer

A team of researchers at the MedUni Vienna has confirmed in a recent study its new concept for the targeted treatment of ovarian cancer. The concept is intended to better control the development of resistance and improve treatment outcomes.

29 Sep 2015

Research posters support utility of EKF’s PointMan DNA enrichment technology for rapid detection of lung cancer mutations

EKF, announces two research posters supporting application of PointMan™ DNA enrichment technology, for rapid and sensitive detection of lung cancer mutations.

From EKF Diagnostics 29 Sep 2015

Philip Chapper & Co to showcase new partner products at Europe’s largest pharmaceutical trade fair

Philip Chapper & Company Ltd, a UK company with over 40 years’ experience within medical supplies, is to showcase innovative products from new suppliers at the industry’s largest European trade fair.

28 Sep 2015

Researchers develop methodology to monitor changes in DNA methylation patterns in individual cells

Whitehead Institute researchers have developed a methodology to monitor changes in DNA methylation over time in individual cells.

26 Sep 2015

Protein-coding gene identified as tumor suppressor for acute myeloid leukemia

A protein-coding gene called hnRNP K has been identified as a tumor suppressor for acute myeloid leukemia (AML), a finding that could be important for investigating how best to target treatment of a blood cancer striking mostly older individuals.

24 Sep 2015

Pabetalone (RVX-208) to be tested in proof-of-concept pilot study in complement mediated diseases

Resverlogix Corp. announced today the commencement of an Orphan Disease Program specific for Complement Mediated Diseases. New data generated by Resverlogix has demonstrated that BET inhibition by apabetalone (RVX-208) has effects on multiple biological pathways that underlie disease pathology.

24 Sep 2015

Study demonstrates potential of FCPCs as new source for cartilage regeneration

The self-repair of injured cartilage is difficult for several reasons, foremost of which is the lack of blood supply to the tissue. Therapeutic efforts aimed at cartilage repair are often not optimal. Surgical repair techniques often lead to the formation of fibrocartilage, which is weaker and less durable. Although cell transplantation aimed at cartilage repair has been carried out using mesenchymal stem cells (MSCs), varying outcomes have resulted, despite the propensity of MSCs to proliferate and differentiate.

23 Sep 2015

AmpliPhi's novel bacteriophage therapy demonstrates comparable efficacy to vancomycin in S. aureus lung infection model

AmpliPhi Biosciences Corporation, a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced experimental results highlighting that its prototype bacteriophage cocktail demonstrated comparable efficacy to vancomycin in reduction of Staphylococcus aureus in a murine lung infection model.

22 Sep 2015

$Common Alzheimer's disease drug increases bone density, reduces fracture risks$

Common Alzheimer's disease drug increases bone density, reduces fracture risks

The most common drug used to treat Alzheimer's disease increases bone mass in mice, according to one of the first research articles published in the new open access journal Heliyon. The authors of the study, from Saitama Medical University in Japan, say this means the drug could also be used to treat bone loss diseases like osteoporosis and periodontitis, following further clinical research.

21 Sep 2015

Combination of TXA709 and cefdinir demonstrates synergistic antibacterial activity against MRSA

TAXIS Pharmaceuticals, a drug-discovery company focused on developing a new class of antibiotic agents to treat life-threatening, multidrug-resistant bacterial infections, announced the presentation of results demonstrating the synergistic antibacterial activity of its lead clinical candidate, TXA709, when combined with cefdinir, a third-generation cephalosporin antibiotic.

19 Sep 2015